CDK4 and breast cancer: The combination of palbociclib, a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6, and ovarian suppression with letrozole significantly prolonged progression-free survival in women with ER+/HER2– advanced breast cancer in the PALOMA-3 (NCT01942135) study (43).